Jul 01, 2025
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 27, 2025
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 27, 2025
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jul 01, 2025 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.97
CHANGE
0.16 (8.84%)
